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ABSTRACT
Background and aims CD8 T cells are central to the
control of hepatitis C virus (HCV) although the key
features of a successful CD8 T cell response remain to
be deﬁned. In a cohort of Irish women infected by
a single source, a strong association between viral
clearance and the human lecucocyte (HLA)-A*03 allele
has been described, and the aim of this study was to
deﬁne the protective nature of the associated CD8 T cell
response.
Methods A sequence-led approach was used to identify
HLA-A*03-restricted epitopes. We examine the CD8 T
cell response associated with this gene and address the
likely mechanism underpinning this protective effect in
this special cohort, using viral sequencing, T cell assays
and analysis of ﬁtness of viral mutants.
Results A strong ‘HLA footprint’ in a novel NS3 epitope
(TVYHGAGTK) was observed. A lysine (K) to arginine (R)
substitution at position 9 (K1088R) was seen in
a signiﬁcant number of A*03-positive patients (9/12)
compared with the control group (1/33, p¼0.0003).
Threonine (T) was also substituted with alanine (A) at
position 8 (T1087A) more frequently in A*03-positive
patients (6/12) compared with controls (2/33, p¼0.01),
and the double substitution of TK to AR was also
observed predominantly in HLA-A*03-positive patients
(p¼0.004). Epitope-speciﬁc CD8 T cell responses were
observed in 60% of patients three decades after
exposure and the mutants selected in vivo impacted on
recognition in vitro. Using HCV replicons matched to the
viral sequences, viral ﬁtness was found to be markedly
reduced by the K1088R substitution but restored by the
second substitution T1087A.
Conclusions It is proposed that at least part of the
protective effect of HLA-A*03 results from targeting of
this key epitope in a functional site: the requirement for
two mutations to balance ﬁtness and escape provides an
initial host advantage. This study highlights the potential
protective impact of common HLA-A alleles against
persistent viruses, with important implications for HCV
vaccine studies.
INTRODUCTION
Hepatitis C virus (HCV) is a single-stranded RNA
virus and replication occurs through the NS5B-
encoded RNA polymerase which lacks proof reading
ability.
1 As a consequence, mutations are readily
generated and are subject to immune selection
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Signiﬁcance of this study
What is already known about this subject?
< Hepatitis C virus (HCV) infection is a leading
cause of cirrhosis and liver disease globally.
< Functional CD4 and CD8 T cells are thought to
be critical to the process of viral clearance,
although many aspects of the nature of
a successful response remain to be deﬁned.
< The occurrence of a large single-source outbreak
of HCV in Ireland has provided clear insights into
the natural history of HCV, and genetic studies
of this unque cohort have previously identifed
the class I allele human leucocyte antigen
(HLA)-A*03 as an independent and signiﬁcant
determinant of viral clearance (OR 2.8).
< We examine the CD8 T cell response associated
with this gene and address the likely mechanism
underpinning this protective effect in this special
cohort.
What are the new ﬁndings in this study?
< We identify a novel T cell epitope restricted by
HLA-A*03(NS31080e1088)whichiscommonly
targeted by women in this cohort (60%).
< Immune pressure imposed by CD8 T cells
appears to drive the selection of an escape
mutation at a key anchor site within the epitope
(K1088R, p¼0.0003). A second common substi-
tition is also observed (T1087A, p¼0.01) in this
group.
< This study shows that the K1088R substitution
is associated with a signiﬁcant loss of ﬁtness;
however, the second substitution (T1087A)
appears to compensate this and restores viral
ﬁtness.
< The protective effect of the HLA-A*03 allele may
thus potentially be explained by the requirement
for two mutations which balance ﬁtness and
escape.
How might this study impact on clinical
practice in the future?
< Unlike other protective alleles, HLA-A*03 is
a prevalent allele (w20% of the population).
Identifying important epitopes linked to protec-
tion in HCV has important implications with
respect to HCV vaccine studies.
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Hepatologypressure. Mutations that facilitate immune escape are used by
the virus to establish persistence.
23Approximately 20% of those
exposed will clear the infection spontaneously.
1 The factors that
determine outcome after HCV infection have been extensively
investigated and there is substantial immunological evidence
that the cellular immune response is a key component in viral
clearance. Studies have shown that the appearance of the Tcell
response within the liver coincides temporally with control of
viral replication.
4 Furthermore, antibody-mediated depletion of
CD4 and CD8 Tcells in chimpanzees re-challenged with autol-
ogous virus was associated with persistent viraemia.
56A study
which examined the relationship between major histocompati-
bility complex (MHC) class I alleles and viral outcome also
strongly supports a key role for T cells in determining viral
clearance. This study was performed on a group of Irish women
who were iatrogenically infected with HCV in 1977 through the
receipt of contaminated anti-D immunoglobulin.
7 Unlike other
class I association studies in HCV, this was unique in that all
patients were of a single gender, of similar age and ethnic
background and had all been infected by a single genotype (1b)
from a common donor. HLA-B*27, HLA-A*03 and HLA-Cw*01
as well as a number of class II alleles were associated with viral
clearance.
The reasons why T cells fail to control viraemia remains
a critical question. One of the key immune evasion strategies
employed by the virus is the development of escape mutations
in T cell epitopes. The occurrence of escape mutations in
targeted CD8 Tcell epitopes is documented in HCVand has been
shown to occur in epitopes restricted by a number of alleles.
8 9
Escape mutations may also provide critical information about
the nature of the T cell response within a given population.
Signiﬁcant T cell responses within a population will result in
selection pressure and results in mutations emerging in an HLA-
dependent fashion (‘footprints’). This identiﬁes crucial responses
linked to the presenting allele and can be an important tool in
recognising T cell epitopes. In the case of a single-source
outbreak where the inoculating sequence is known and genetic
divergence is limited, ‘footprints’ are particularly useful for this
purpose. Escape mutations may abrogate the Tcell response and
promote viral persistence; however, since mutations may also
lead to impairment of viral ﬁtness, their overall impact on
disease outcome is still unclear. Viral mutations which lead to
impairment of replicative ﬁtness may still provide overall
selective advantage for the pathogen in the face of strong Tcell
pressure. Furthermore, compensatory mutations may arise,
which lead to recovery of ﬁtness, although this requires further
viral adaptation. In the case of HIV this may take some time to
develop, providing the host with a prolonged period of protec-
tion.
10 Since in HCV the virus has a relatively short window in
which to establish persistence, the issue of ﬁtness cost and the
requirement for compensatory mutations could be of high
importance in deﬁning the protective nature of a Tcell response
and thus the HLA allele.
While much attention, especially in the HIV ﬁeld, has been
paid to rare alleles, particularly from the HLA-B locus
11,H L A -
A*03 is relatively common (w20% in Caucasian populations)
(http://www.allelefrequencies.net), and thus understanding how
this allele exerts its protective effect has important implications
for the population with respect to vaccine design. In this study,
we aimed to understand the mechanism of protection afforded
by HLA-A*03 by identifying key epitopes associated with it. We
have identiﬁed a key epitope close to the active site of the NS3
protease which is routinely targeted in HLA-A*03-positive
patients. Furthermore, we show that a single escape mutation is
accompanied by a signiﬁcant impairment of viral ﬁtness, which
may be rescued by mutation at a second covariant site. Our
results provide important new data supporting the role of HLA-
A*03 as an important driver of protective immune responses in
HCV and offers insight into the formidable interplay between
host and virus in determining outcome of infection.
MATERIALS AND METHODS
Study population
The study population is derived from a group of Irish women
who were exposed to HCV (genotype 1b) through the receipt of
contaminated anti-D immunoglobulin in 1977e1979. This
group has been described in detail.
7 12 Ethics approval for this
study was obtained from the Research and Ethics Committees
at St James’ Hospital and St Vincent’s Hospital. Informed
consent was obtained from all patients. Peripheral blood
mononuclear cells (PBMCs) were isolated by density centrifu-
gation and, following centrifugation of whole blood, plasma
was obtained and frozen at  808C.
HCV and control peptides
Fifteen HLA-A*02-restricted HCV epitopes
13 (supplementary
table 2 online) were chosen using the predominant amino acid
sequences which were either present in the donor (GenBank:
AF313916) or circulating in the recipients.
14 Control epitopes
from inﬂuenza, cytomegalovirus (CMV) and EpsteineBarr virus
(EBV) were also chosen (Supplementary table 2). A set of 300
20mer overlapping peptides (average purity 86%) were used
(Pro-immune, Oxford, UK) and were based on the genotype 1b
donor sequence (GenBank: AF313916).
Identiﬁcation of candidate HLA-A*03-restricted HCV-speciﬁc
CD8 T cell epitopes
Predicted epitopes were identiﬁed using a combination of
different prediction programs (Bimas, SYFPEITHI, Jenner,
P r o P r e d1 ,R a n k p e p ,M A P P Pa n dN e tM H C ) .E p i t o p e sw i t ht h e
highest ranking were chosen (supplementary table 1 online). In
order to generate CD8 T cell lines, we stimulated PBMCs with
three of the predicted HLA-A*03-restricted HCVepitopes and two
EBV-derived epitopes. These were the two ‘footprint’ epitopes NS3
1080e1088 TVYHGAGTK and NS5B 2510e2518 KLTPPHSAK
and also a third non-‘footprint’ epitope NS5B 2562e2570
EVFCVQPEK. The control peptides were RLRAEAQVK and
R V R A Y T Y S K( s e es u p p l e m e n t a r yt a b l e1f o rm o r ed e t a i l s ) .
Sequencing and in silico protein translation and alignment
Sera samples from cohort subjects were collected between 1996
and 2002 and stored at  808C (St James’ Hospital, Dublin,
Ireland). Stored patient sera were available on 15 previously
identiﬁed HLA-A*03-positive patients.
7 Viral RNAwas extracted
from plasma using the Roche Cobas Amplicor HCV Kit and then
used in three one-step reverse transcriptionePCR system reac-
tions (SuperScript III One-Step RT-PCR, Invitrogen, Paisley, UK)
to amplify the viral genome (from the core to the NS5B region).
The ﬁrst-round template was subsequently used in nested
second-round PCRs (Taq DNA polymerase, Roche, Burgess Hill,
UK). Resultant PCR products were bulk-sequenced using the
ABI BigDye Terminator Sequencing Kit (Applied Biosystems,
Warrington, UK). Due to the age of the samples and the likely
event of variability in parts of the HCV genome targeted by
primers, some samples failed to produce a PCR product and, as
a result, some individuals did not contribute sequence for NS3
(n¼3). Sequence chromatograms were edited using the program
Assign (Conexio Genomics, Freemantle, Australia).
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HepatologyIn silico protein translation was carried out using CLC Bio
Free Workbench (Aarhus, Denmark) software. Using Clustal W
multiple alignment algorithms all sequences were aligned with
the original donor sequence. Epitopes (supplementary tables 1
and 2) were ﬁrst identiﬁed in the donor sequence and all patient
samples. The amino acid sequence of the epitope, throughout
all sequences, was investigated for potentially signiﬁcant
substitutions.
Antigen-speciﬁc CD8 T cell lines
Fresh PBMCs (4310
6) were resuspended in 1 ml of medium and
stimulated with 10 mg/ml peptide and 25 ng/ml interleukin 7 (IL-7;
R&D systems, Abingdon, UK). IL-2 (20 ng/ml, Sigma Aldrich,
Gillingham, UK) and fresh media were added on days 3, 7, 10 and
12. Cells were restimulated with 10 mg/ml of the corresponding
peptide on day 7 and harvested for assays on day 14.
The protocol for intracellular cytokine staining is available in
the supplementary methods section.
Statistical analysis
To determine the statistical signiﬁcance of the amino acid
substitutions within the deﬁned epitopes, the Fisher exact test
was used, and a p value of <0.05 was considered signiﬁcant. The
paired Student t test was used to compare frequencies of
tetramer-positive populations, and a p<0.05 was considered
signiﬁcant.
Construction of mutations
The previously described HCV replicon pFK-i341PiLucNS3-39-
ET
15 was used for the transient replication assay. PCR-based site-
directed mutagenesis was used to obtain the escape mutants.
Primer pairs were used as described in the supplementary
methods. The PCR fragments were cloned in pGEMT easy
vector. Selected clones were sequenced to conﬁrm the presence of
the mutation. Fragments were then digested with restriction
enzymes NotI and MluI, and ligated into linearised vector.
RNA transcription and electroporation
Mutant plasmids along with the wild type and GND negative
control were linearised with PvuI enzyme and transcribed in
vitro using the T7 RNAmax (Promega, Southampton, UK) and
DNase treated. RNA was extracted with acid phenol chloroform
and stored at  208C. A 20 mg aliquot of puriﬁed RNAwas mixed
with 400 ml of Huh-7 cells (10
7 cells/ml) using the gene pulser
(Bio-Rad, Hemel Hempstead, UK) adjusted to deliver one pulse
of 0.25 kV and 960 mFd. Cells were then seeded into 6-well
cluster plates and cultured in the presence of complete media.
Cell culture conditions are described in the supplementary
methods section.
Luciferase assay
The Bright-Glo Luciferase assay system (Promega) was used to
analyse viral ﬁtness using luciferase as the reporter. Luciferase
readouts were taken at 4, 24, 48 and 72 h post-transfection. Each
assay was compared with the wild type (positive control) and
the replication-deﬁcient mutant (negative control GND). All
values were normalised to the 4 h RNA value (set at 100%) and
also further normalised to the wild type. The results are
presented as the mean of three independent experiments.
RESULTS
Ex vivo T cell responses are not detectable in patients
infected with HCV three decades previously
Ex vivo Elispot analysis of PBMCs from six HLA-A*03-positive
patients (table 1) with spontaneous resolved infection showed no
signiﬁcant CD8 T cell responses to 26 HCV epitopes (ﬁgure 1A
and supplementary table 1). Similar results were obtained when
we examined responses to previously identiﬁed immunodo-
minant HLA-A*02-restricted epitopes (supplementary table 2) in
17 HLA-A*02 patients (ﬁgure 1B and supplementary table 5).
In parallel we also screened the entire genome for novel Tcell
responses. Using a set of overlapping peptides (20mers
Table 1 Details of HLA and HCV RNA status of HLA-A*03-positive patients included in the study
Patient no.* HLA class I HLA class II HCV RNA status
A*03 assays
(tetramer frequency %) Sequence
15 A*03,03,B*07,44, C*07,16 DR*1501,1302 DQ*0602,0609 PCR+ Culture (neg) TVYHGAGSK
1537 A*01,03,B*07,08 C*07,08 DR*1501, 1501, DQ*0602, 0602 PCR+ TVYHGAGAR
39 A*01,03,B*37,57, C*06,06 DR*0701,0101, DQ*0501,3032 PCR+ TVYHGAGAR
1543 A*03,24,B*35,51, C*04,17 DR*0407,1601, DQ*0301,0501 PCR+ TVYHGAGAR
77 A*01,03,B*07,08, C*07,07 DR*3011,1501, DQ*0201,0602 PCR+ TVYHGAGAR
60 A*02,03,B*07,44, C*05,07 DR*4048,4013, DQ*0301,0302 PCR  ve (Treated) Culture (14.1%) TVYHGAGTR
1548 A*02,03,B*14,18, C*07,08 DR*401,1104, DQ*0301,0301 PCR+ TVYHGAGAR
1549 A03,23,B*07,47, C*04,07 DR701,1501, DQ*0202,0602 PCR+ TVYHGAGAR
1552 A*03,30,B*17,18, C*05,07 DR*3011,1501, DQ*0201,0602 PCR+ TVYHGAGTK
1562 A*03,30,B*13,44, C*06,16 DR*0701,0701, DQ*0202,0202 PCR+ XXYHGAGTR
1571 A*02,03,B*14,57, C*08,10 DR*1501,1301, DQ*0602,0603 PCR+ TVYHGAGTK
1587 A*02,03,B*14,57, C*06,08 DR*0701,1303, DQ*0301,3023 PCR+ TVYHGAGTR
106 A*01,03,B*14,37, C*06,08 DR*0401,1201, DQ*0301,0609 SR Culture (3.9%) e
49 A*03,68,B*07,15, C*06,07 DR*3011,0701, DQ*0602,0302 SR Culture (6.8%), Elispot e
29 A*01,03,B*07,57, C*06,07 DR*3011,0701, DQ*0201,3032 SR Culture (4.4%), Elispot e
113 A*01,03,B*07,08, C*07,08 DR*1501,1501, DQ*0602,0602 PCR+ Culture (neg) e
105 A*03,26,B*27,49, C*01,07 DR*101,1101, DQ*0301,0501 SR Culture (neg) e
102 A*02,03,B*14,44,C*05,08 DR*0101,0404, DQ*0501,0302 SR Culture (neg) e
110 A*02,03,B*14,44, C*05,08 DR*0401,0101, DQ*0301,0302 SR Culture (2.83%) e
109 A*02,03,B*07,44, C*05,07 DR*0401,0401, DQ*0301,0302 SR Culture (1.36%) e
40 A*02,03,B*14,60, C*08,10 DR*1501,1501, DQ*0602,0602 SR Elispot e
42 A*01,03,B*07,57, C*06,07 DR*1501101, DQ*0602,0501 SR Elispot e
50 A*02,03,B*07,44, C*05,07 DR*1501101, DQ*0602,0501 SR Elispot e
52 A*01,03,B*07,07, C*07,07 DR*0101,0404, DQ*0501,0302 SR Elispot
HCV, hepatitis C virus; HLA, human leucocyte antigen; SR, spontaneous resolver. Class II alleles are DRB1 or DQB1.
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Hepatologyoverlapping by 10 amino acids) spanning the entire HCV poly-
protein (AF313916dgenotype 1b), Elispot assays conﬁrmed the
absence of detectable ex vivo Tcell responses in women derived
from this cohort (ﬁgure 1C and supplementary table 6).
To determine if low-frequency responses were present,
peptide-speciﬁc cell lines were generated by culturing fresh
PBMCs in the presence of peptide for 14 days. Three immuno-
dominant HLA-A*02-restricted epitopes (NS3 1073e1081
CINGVCWTV and CVNGVCWTV, NS3 1406e1415
KLSGLGLNAV, NS4 1987e1995 VLSDFKTWL) as well as
control peptide epitopes from CMV and EBV were used to
stimulate the cells, and cultured lines were obtained in eight
HLA-A*02-positive patients (supplementary table 7). Two
epitopes generated detectable CD8 Tcell responses (ﬁgure 2A,B).
Responses targeting the NS3 1073e81 epitope were observed in
all 8 (100%) patients by tetramer staining. In addition, 2 of the 8
patients (25%) also had detectable responses to the NS3
1406e15 epitope. When we tested patients for CD8 T cell
responses to the same set of tetramers ex vivo, we were unable
to observe antigen-speciﬁc cells.
HLA ‘footprinting’ reveals novel CD8 T cell responses
restricted by HLA-A*03
In order to deﬁne the HLA-A*03-restricted CD8 Tcell response
further, we adopted an alternative sequence-directed approach.
To assess the impact of HLA-A*03-mediated T cell selection
pressure, we determined the bulk sequence of the non-structural
region of the viral genome in the serum of HLA-A*03-positive
and -negative patients derived from the cohort (table 1 and
supplementary table 8). The sequences were then aligned with
that of the donor and the 26 HLA-A*03-restricted epitopes
(Supplementary table 1) were identiﬁed. A comparison of the
epitope sequences in HLA-A*03-positive and -negative individ-
uals revealed two clear HLA-A*03 ‘footprints’ (ﬁgure 3). The ﬁrst
was located within the NS3 1080e88 TVYHGAGTK epitope.
Lysine (K) was substituted with arginine (R) at position 9
(K1088R) in 9/12 (75%) A*03-positive patients compared with
1/33 (3%) controls (p¼0.0003). Threonine (T) was also
Figure 1 Magnitude of CD8 T cell responses as determined by ex vivo
interferon g ELISpot. HCV-speciﬁc CD8 T cell responses are absent ex
vivo in all patients. (A) HLA-A*03-positive patients, n¼6. All patients
had spontaneously resolved infection. (B) HLA-A*02-positive patients,
n¼17 (6 patients had spontaneous resolved infection and 11 had
persistent infection. (C) Whole genome assay in HLA diverse individuals,
n¼8 (4 spontaneous resolvers and 4 persistently infected). Responses
are presented as the mean of duplicate wells after substraction of
background. Summation of spot-forming units (SFU) is expressed per
1310
6 peripheral blood mononuclear cells (PBMCs). CMV, cytomega-
lovis, EBV, EpsteineBarr virus; HCV, hepatitis C virus; HLA, human
leucocyte antigen; PHA, phyto-haemagglutinin.
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Figure 2 CD8 T cell responses to HLA-A*02-restricted epitopes in
cultured lines. (A) Group data. (B) Representative dot plots of the CD8 T
cell responses to the NS3 1073e81 epitope (CVNGVCWTV or
CINGVCWTV) in two patients with resolved infection (patient 107 and
60). (C) Representative dot plots of tetramer responses to HLA-A*02-
restricted control EBV and CMV epitopes. CMV, cytomegalovis, EBV,
EpsteineBarr virus; HLA, human leucocyte antigen.
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Hepatologysubstituted with alanine (A) at position 8 (T1087A) in 6/12
(50%) A*03-positive patients compared with 2/33 (6%) controls
(p¼0.01). The double substitution of TK to AR is also observed
predominantly in HLA-A*03-positive patients (6/12, 50%)
compared with 1/33 (3%) in controls and was also found to be
signiﬁcantly linked to A*03 (p¼0.004). The second ‘footprint’
was located in the NS5B epitope (NS5B 2510e18 KLTPPHSAK).
Lysine (K) was substituted with arginine (R) at position 9 in
8/15 (53%) A*03-positive patients compared with 2/45 (4%)
A*03-negative patients (p¼0.001). A second common substitu-
tion was also observed at position 1 in both HLA-A*03-positive
and -negative patients, but was not signiﬁcant. The 15 HLA-
A*02-restricted epitopes (supplementary table 2) were also
examined, but no HLA association was observed (supplementary
ﬁgure 2).
HLA-A*03-restricted NS3 1080e88 epitope is targeted by CD8
T cell responses in resolved HCV infection
These HLA-A*03-speciﬁc ‘footprints’ provide strong evidence
that they are likely to be in vivo targets of the CD8 T cell
repertoire. To assess this, we generated peptide-speciﬁc T cell
lines corresponding to the ‘footprint’ epitopes (NS3 1080e88
TVYHGAGTK and NS5B 2510e18 KLTPPHSAK) and to another
predicted epitope NS5B 2562e70 EVFCVQPEK. Two control
peptides derived from EBV were also included (supplementary
table 1). A total of 6/10 patients (table 1) with resolved infection
demonstrated CD8 T cell responses to the NS3 1080e88
TVYHGAGTK epitope by tetramer analysis (ﬁgure 4A,B). All six
patients had resolved infection either spontaneously or with
antiviral treatment. CD8 Tcell responses were not detectable in
lines stimulated with the other two HCV peptide epitopes
(ﬁgure 4A).
Impact of escape mutations on CD8 T cell recognition
To address further the impact of the amino acid substitutions on
T cell recognition, cell lines speciﬁc for the epitope were tested
for recognition of TVYHGAGTK (wild type) or the escape
mutants TVYHGAGAR or TVYHGAGTR in three patients who
had detectable CD8 Tcell responses. In all patients, the secretion
of interferon g was reduced in response to the peptide with
both the escape mutations (TVYHGAGAR or TVYHGAGTR)
(ﬁgure 5A,B).
To assess the binding ability of the epitopes to the HLA-A*03
allele, we used two different bio-informatic programs (Net
MHC and BIMAS) to identify the predicted binding of both the
wild-type (TVYHGAGTK) and the mutant epitopes
Figure 3 Two HLA-A*03 ‘footprints’ in predicted hepatitis C virus
epitopes. Signiﬁcant sequence variation is seen in the NS3 1080e88
TVYHGAGTK epitope. Lysine (K) is substituted with arginine (R) at
position 9 (K1088R) in 9/12 patients (75%) in the A*03-positive group
compared with 1/33 (3%) in the control group, p<0.0003. Furthermore,
the threonine (T) at position 8 is frequently substituted with alanine
(A) (T1087A) in 6/12 (50%) HLA-A*03-positive patients compared with
A*03-negative patients (2/33, 6%), p¼0.01. The double substitution
TK1087AR is also observed in a signiﬁcant number of HLA A*03-positive
patients (50%) compared with controls (3%), p¼0.004. A second
HLA-A*03 ‘footprint’ is also present in the hepatitis C virus NS5B
protein. Signiﬁcant sequence variation in seen in the NS5B 2510e18
KLTPPHSAK epitope. Lysine (K) is substituted with arginine (R) at
position 9 (K2518R) in 8/15 (53%) in the A*03-positive group compared
with 2/45 (4%) in the control group (p¼0.001). Lysine (K) is also
substituted with methionine (M) in both groups. Its association with
HLA-A*03 is not signiﬁcant (p¼0.2). X indicates no sequence available.
Statistical comparison by the Fisher exact test. HLA, human leucocyte
antigen.
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Figure 4 CD8 T cell responses to the HLA-A*03-restricted ‘footprint’
epitope NS3 1080e88 in cultured cell lines. (A) Overall data set; n¼10
(seven patients had spontaneously resolved infection, one patient
resolved with antiviral therapy and two patients had chronic infection)
(B) Representative dot plots showing tetramer responses to the NS3
1080e88 epitope in two patients (both resolvers) (C) Dot plots
demonstrating tetramer responses to the HLA-A*03-restricted control
EBV epitopes. EBV, EpsteineBarr virus; HLA, human leucocyte antigen.
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Hepatology(TVYHGAGAK, TVYHGAGTR and TVYHGAGTR. This search
also conﬁrmed a signiﬁcant reduction in the predicted binding
ability of the variant epitopes containing the K1088R substitu-
tion (ﬁgure 5C).
We also cultured PBMCs in the presence of peptides repre-
senting either the wild-type epitope (TVYHGAGTK) or mutant
peptides which possessed either of the single mutations observed
(TVYHGAGTR and TVYHGAGAK) or the double mutant
(TVYHGAGAR), and looked for expansion of antigen-speciﬁc
T cells. After 14 days, these lines were analysed by tetramer
staining. Notably in four out of ﬁve patients, a reduction in the
number of tetramer-positive CD8 T cells was observed in cells
stimulated with the single mutant TVYHGAGAK, although this
was not signiﬁcant. Cultured cell lines stimulated with peptides
containing the K1088R mutation (TVYHGAGTR or TVYH-
GAGAR) showed almost no stimulation of antigen-speciﬁc CD8
Tcells (ﬁgure 6A,B and C).
The escape mutant TVYHGAGTR is associated with ﬁtness cost
but the double mutant TVYHGAGAR compensates to restore
optimal viral replication
To determine the effect of the mutations observed in the HLA-
A*03-positive patients, we assessed their impact on viral repli-
cation efﬁciency. Mutations were introduced into a subgenomic
replicon (genotype 1b strain) carrying a ﬁreﬂy luciferase reporter
gene. In this strain the wild-type sequence of the epitope carries
serine at position 8 (TVYHGAGSK). We therefore introduced the
threonine substitution here (TVYHGAGTK) and this mutant
construct served as our wild type (as observed in the Irish
cohort). Two further epitope mutants were createddone bearing
the single K1088R substitution at position 9 and the
other bearing the double substitution T1087A and K1088R.
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IC50 value)
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Binding
affinity
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Binding
ability
TVYHGAGTK 38 3.0 Strong binder
TVYHGAHAK 36 3.0 Strong binder
TVYHGAGTR 193 0.6 Weak binder
TVYHGAGAR 169 0.6 Weak binder
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Figure 5 Immune escape by selected peptides in NS3 1080e88. (A)
Peripheral blood mononuclear cells from three patients with resolved
infection were cultured in the presence of the NS3 1080e88 peptide
TVYHGAGTK. They were then re-stimulated with the wild-type NS3
TVYHGAGTK or the escape mutant (TVYHGAGTR and TVYHGAGAR)
peptides (10 mg/ml ﬁnal concentration). The ability to secrete interferon
g (IFNg) was analysed by intra-cellular cytokine staining (ICS). A
signiﬁcant reduction in IFNg secretion was observed in lines stimulated
with the mutant peptides TVYHGAGTR and TVYHGAGAR, *p¼0.04
(Student t test). (B) A peptide titration for the wild type and the escape
mutants was performed on subject 49. The peptide concentration is
presented as mg/ml. (C) The predicted binding ability of the wild-type
and variant peptides identiﬁed in two bio-informatic programs (NetMHC
and BIMAS). The lysine to arginine substitution at position 9 causes
a signiﬁcant reduction in the predicted binding ability. The NetMHC
program relies on artiﬁcial neural networks which are capable of
performing sensitive, quantitative predictions of peptide binding to the
MHC (major histocompatibility complex) class I molecules. These
systems have been designed to predict binding versus non-binding
peptides, and their binding abilities are presented as an estimated afﬁnity
in nM.
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Figure 6 Variant peptides fail to stimulate NS3 1080e88-speciﬁc CD8
T cells. Antigen-speciﬁc lines were generated in response to the wild-
type (WT) peptide (TVYHGAGTK) or variants that contained either
a single mutation (TVYHGAGAK or TVYHGAGTR) or the double mutation
(TVYHGAGAR). (A) The lysine (K) to arginine (R) mutation at position 9
(TVYHGAGTR) and (TVYHGAGAR) caused a signiﬁcant reduction in the
binding of the WT tetramer (p¼0.03), while the threonine (T) to alanine
(A) change alone (TVYHGAGAK) led to a reduction in binding in four
patients (p¼ns). (B) Results after normalisation of the WT (TK-speciﬁc)
cells to 100%. (C) Representative dot plots (patient 29) are shown.
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HepatologyThe replication efﬁciency of these mutants was then compared
with the wild-type sequence and a replication-defective replicon
(GND) at a number of time points (0, 4, 12, 24 and 48 h). We
observed a signiﬁcant reduction in the replication efﬁciency in
mutants bearing the single substitution K1088R at all time
points. In contrast, the mutant carrying the double substitution
(T1087A and K1088R) was associated with a viral replication
efﬁciency which was w98% of that of the wild type at 72 h
(ﬁgure 7). The previous functional T cell experiments suggest
that only the K1088R mutation is necessary to achieve CD8 T
cell escape; however, this single substitution is observed only
rarely in vivo in the Irish cohort. These data indicate that this
substitution is associated with a marked loss of viral ﬁtness. The
development of the double substitution appears to restore viral
replication efﬁcency and thus supports its importance as a key
compensatory mechanism.
DISCUSSION
HLA-A*03 was found to be a protective allele in determining
viral clearance in HCV infection in a study of patients infected
from a single source.
7 We hypothesised that this effect may be
due to a single epitope or a set of immunodominant epitopes
restricted by this allele. In order to identify HLA-A*03-restricted
responses in this cohort, we adopted two approaches. In the
ﬁrst, we chose a set of 26 HLA-A*03-restricted epitopes based on
previous publications and prediction programs using the known
sequence of the inoculating virus. We were unable to detect CD8
T cell responses ex vivo in patients with either resolved or
persistent infection irrespective of their HLA type. This result
differs from that of Takaki et al who examined ex vivo responses
to HLA-A*02-restricted epitopes in women infected from
a similar single-source outbreak, where vigorous responses were
observed in the resolvers but not in the chronically infected
group.
16 The differences in the CD8 T cell responses observed
may reﬂect the natural waning of the cellular responses to HCV
three decades after a single exposure (as occurs with humoral
responses). Other factors such as the genetic background, tech-
nical differences and the dose of inocula may also have played
a role. To determine if persistent responses were present after
re-stimulation, we cultured PBMCs in the presence of speciﬁc
peptide. We were able to conﬁrm that antigen-speciﬁc responses
persist in this cohort but that the precursor frequency is low and
requires re-stimulation prior to detection.
As ex vivo Tcell responses were not detectable in this cohort,
we used a sequence-led approach to establish Tcell targets. HLA-
associated ‘footprint’ epitopes provide a sensitive measure of
where the important CD8 T cell-mediated activity is being
exerted. We were thus able to identify two clear HLA-A*03
‘footprints’ in the NS3 1080e88 and the NS5B 2510e18
epitopes.
In the NS3 1080e88 TVYHGAGTK epitope, there are two
signiﬁcant substitutions, K1088R at position 9 (P9) and T1087A
at position 8 (P8), in HLA-A*03-positive patients. Furthermore,
in a signiﬁcant number of HLA-A*03 patients, these two
mutations (T1087A and K1088R) occur together. Anchor posi-
tions represent the preferred amino acid side chain that ﬁts into
pockets within the MHC groove. The anchor motifs for HLA-
A*03 molecules usually occur at P2 and P9
17 and thus the
K1088R mutation at P9 is likely to facilitate escape from this
immunodominant response in vivo. To support this, we have
shown that interferon g production from cell lines stimulated
with peptides containing the K1088R mutation is reduced and
that mutant peptides failed to stimulate antigen-speciﬁc prolif-
eration in vitro.
The above ﬁndings support the role of CD8 T cell escape as
a major mechanism for viral persistence but do not explain how
HLA-A*03 mediates its protective effect. In HIV infection, the
protective effects associated with class I alleles, for example
HLA-B*27, have been attributed to the targeting of epitopes
which lie in structurally or functionally constrained regions.
Escape mutations occurring within these epitopes incur a ﬁtness
cost which reduces viral replication and attenuates the
virus.
18e20 The ﬁtness cost of escape mutations has also been
studied in HCV although to a much lesser extent. In a recent
study, the impact of amino acid substitutions in a HLA-B*08-
restricted epitope was analysed and a signiﬁcant ﬁtness cost was
observed.
21 The NS3 1080e88 TVYHGAGTK epitope lies within
the NS3 region which codes for a bifunctional protein with both
protease activity and NTPase helicase activity. Mutations at key
catalyic sites including His1083, which lies within the TVYH-
GAGTK epitope, have been shown to abolish cleavage of the non-
structural proteins.
22 Thus, substitutions occurring within this
region are likely to have an effect on viral processing and repli-
cation. Supporting this, the adjacent immunodominant HLA-
A*02-restricted epitope NS3 1073e81 CVNGVCWTV is
routinely targeted in A*02-positive individuals but is relatively
conserved, and a previous study indicates that substitutions
within this epitope signiﬁcantly affect its function.
23
We therefore speculated that a dominant CD8 Tcell response
associated with HLA-A*03 might drive escape mutations that
reduce viral ﬁtness and contribute to the favourable outcomes by
either delaying the ﬁxation of substitutions or promoting
a weakened virus. In the case of several HIV epitopes linked to
protective alleles, compensatory mutations arise in adjacent
regions of the genome and their function is primarily to restore
ﬁtness capacity.
10 20 24 In HCV infection, the protective allele
HLA-B*27 has been linked to a dominant CD8 T cell response
associated with the NS5B 2841e49 ARMILMTHF epitope.
Escape from immune recognition in this case appears to require
multiple mutations and these mutations do not appear to have
a compensatory function.
25 We postulated that the development
of the T1087A mutation within the NS3 1080e88 epitope may
reﬂect accessory changes that are compensatory in the setting of
restoring viral ﬁtness or are occurring to complete the evolution
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Figure 7 The percentage replication efﬁciency of mutants compared
with the wild type (TK). Representative time course of mutants TR and
AR compared with the wild type (TK) and the negative mutant (GND) at
48 and 72 h. Replicative capacity is expressed as a percentage after
normalisation to the 4 h input RNA value (reﬂecting transfection
efﬁciency). Wild-type (TK) was normalised to 100%. The mean6SD of
three independent experiments is shown. Replication efﬁciency of the
mutant TR is signiﬁcantly reduced at both time points while the AR
mutant replicates almost to wild-type levels, indicating a compensatory
role. Student t test was used for statistical analysis.
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hypothesis. This hypothesis is strongly supported by the func-
tional analysis of the replicons in vitro, which revealed a major
compensatory effect of the second T1087A mutation. Further-
more, the structural impact of such mutations is not fully
understood. We modelled the wild-type epitope onto the
existing structure of HCV NS3 (supplementary ﬁgure 3).
26
This revealed strong structural constraints on the lysine residue
at 1088, which stabilises a helical turn. In contrast, threonine
at position 1087 would appear to have much less constraint, and
the mechanism for the associationdwhich is very clear at
a genetic level in vivo and supported by functional studies
in vitrodrequires further speciﬁc analysis to deﬁne its
molecular basis.
There were two clear ‘footprints’ associated with HLA-A*03
epitopes. Although we did not ﬁnd evidence of CD8 T cell
responses to the NS5 2510e18 KLTPPHSAK ‘footprint’ epitope
in this study, we cannot exclude the possibility that persisting
responses are present in the liver or that technical issues may
have precluded their identiﬁcation. The strong ‘footprint’
associated with this epitope in this study is important and may
indicate ongoing selection pressure at some level. This epitope
has previously been identiﬁed in genotype 1a infections
27 and
a ‘footprint’ has also been identiﬁed in other populations
(personal communication, Todd Allen, Boston). It is possible
that the simultaneous targeting of more than one dominant
epitope restricted by HLA-A*03 may be contributing to the
overall protection. Longitudinal studies of the T cell responses
in HLA-A*03 individuals with acute infection will be necessary
to deﬁne the kinetics and hierarchy of these responses. The
degree to which this epitope is targeted in other populations
infected with differing genotypes and subtypes has not yet
been assessed and further studies are required to address this.
Although we were unable to detect ex vivo CD8 T cell
responses to this epitope in the Irish cohort, the highly signif-
icant HLA-A*03 ‘footprint’ provides robust evidence that this
epitope was likely to have been under considerable T cell-
mediated selection pressure relatively early on in the course of
infection. Other studies have indicated that the initial
6 months are pivotal to outcome and that escape mutations
typically occur during this time.
28 Furthermore, these muta-
tions tend to become ﬁxed within the circulating quasispecies,
perhaps reﬂecting ongoing selection pressure in the liver.
2
Although we have not looked for Tcell responses in longitudinal
studies across other populations, several studies have looked for
the presence of HLA-associated footprints in diverse
populations.
29e31 These studies serve as a surrogate marker which
can be used to identify areas of the genome under CD8 T cell-
mediated selection pressure (putative epitopes). To date, none of
these studies has identiﬁed signiﬁcant polymorphisms linked to
the NS3 1080e88 epitope. We therefore speculate that the
immunodominance of this epitope may be subtype speciﬁca n ds o
difﬁcult to identify in the absence of larger studies or subtype-
speciﬁc studies. Our examination of the sequences of this epitope
available in the database also demonstrates that the protective
epitope TVYHGAGTK was found in the majority of genotype 1b
viral strains but not in genotype 1a (supplementary table 4). It is
interesting to note that the protection associated with the HLA-
B*27 allele has been linked to an epitope identiﬁed in genotype 1
viral strains. Indeed, a protective effect of HLA-B*27 was not
identiﬁed in genotype 3 infections in German patients and the
same epitope was not targeted in genotype 3 infections.
32 These
data highlight the need to identify a range of protective T cell
epitopes across all genotypes.
The highly polymorphic nature of the HLA genes poses
signiﬁcant challenges to vaccine design, and extensive diversity
is observed in HLA class I and II associations with susceptibility
and protection in HCV infection in different cohorts.
33 Other
studies have also identiﬁed HLA-A*03 as a critical determinant
of outcome in HCV and hepatitis B virus (HBV). Wang et al
describe an association between viral clearance and HLA-A*03;
however, this association was only identiﬁed in the non-
Caucasian subgroup of the cohort.
34 In a Korean study, HLA-
A*03 was found signiﬁcantly more frequently in chronic HCV
carriers compared with healthy controls.
35 In HBV infection,
HLA-A*0301 has also been identiﬁed as a protective allele.
36
These genetic studies clearly indicate that both the ethnic and
geographic distribution of HLA genes associated with HCV
outcome are different but point to an important interaction
between HLA-A*03 and virus in other cohorts.
While it is well recognised that escape from certain CD8 Tcell
epitopes is likely to be an important mechanism in determining
outcome in HCV infection, it certainly is not a universal ﬁnding
in persistent infection. Komatsu et al previously examined the
viral sequences from a set of chronically HCV-infected patients
in whom CD8 Tcell responses in the liver had previously been
accurately mapped. They found that even in the presence of
persistent intrahepatic T cell responses, only about half of the
patients studied showed evidence of escape.
37 This ﬁnding may
potentially be explained by differences in binding ability, antigen
presentation or functional capabilities. However, the highly
signiﬁcant association between HLA-A*03 and the presence of
the K1088R in chronically infected individuals in this study
provides strong support for CD8 Tcell-mediated selection pres-
sure and indicates that targeting of the wild-type epitope may
have contributed to the protective effect found to be associated
with HLA-A*03. However, even in the 12 HLA-A*03 individuals
with viral sequences available, 25% (3/12) had no evidence of
mutation at the 1088 anchor position, indicating that other
mechanisms were responsible for viral persistence in these
subjects. Recent sequencing of other viral polymorphisms from
this cohort in relation to diverse HLA genes has revealed
a similar picture in other sites across the HCV NS genes, and this
is consistent with previous data.
38 39
In conclusion, we have identiﬁed a novel CD8 Tcell response
associated with the protective HLA-A*03 allele through the use
of a unique genetic set of information available as a consequence
of a single-source outbreak. Furthermore, this setting provides
valuable insights into the complex interplay between host and
pathogen in a tightly deﬁned population. A*03 is a relatively
common allele and thus the protective impact within a popula-
tion is likely to be substantially greater. These ﬁndings have
important implications with respect to vaccine design and reveal
the power of both host and viral genetic approaches to deﬁne the
crucial components of the host response.
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